GSK and Flagship Pioneering announced in July 2024 that they have entered a collaboration to discover and develop a portfolio of “transformational” medicines and vaccines, starting in respiratory and immunology. The agreement will combine GSK’s “disease area expertise and development capability” with Flagship’s “ecosystem of bioplatform companies”, including novel modalities and technologies. The two organisations seek to achieve “major advances” in healthcare.
Building up to a portfolio
GSK and Flagship will begin with $150 million funding to support an “exploration phase” to identify the “most promising concepts” for research and development with Flagship’s bioplatform companies. Following this, the collaboration is intended to identify a portfolio of up to 10 novel medicines and vaccines. These will be subject to an exclusive option by GSK for further clinical development. Flagship and its bioplatform companies will be eligible to receive up to $720 million in upfront, development, and commercial milestones from GSK, alongside preclinical funding and tiered royalties, for each programme acquired.
Chief Scientific Officer at GSK, Dr Tony Wood, looks forward to partnering with the “talented team at flagship” and their bioplatform “ecosystem” to accelerate the pipeline and identify “practice-changing medicines and vaccines”.
“We will use science and technology to deliver best-in-class innovation at pace.”
Flagship’s General Partner and President, Pioneering Medicines, Paul Biondi, identifies a “shared focus on delivering breakthrough medicines for patients”.
“This collaboration is the latest example of Flagship’s Innovation Supply Chain Partnership model, which is designed to generate transformational medicines together with our pharma partners by leveraging our ecosystem of first-in-category bioplatforms to create a sustainable source of treatments for patients with the greatest unmet needs.”
If you’re interested in hearing more on vaccine partnerships, why not come to the Partnerships and Access Track at the Congress in Barcelona this October to learn more from field leaders? Don’t forget to subscribe to our weekly newsletters here for the latest vaccine news.
